Recent Updates
Recently added Catalysts
PRGO Positive Sentiment

Perrigo Announces Quarterly Dividend

Key Takeaway: Perrigo Company plc announced a quarterly dividend of $0.290 per share, which will be paid on December 16, 2025, to shareholders on record as of November 28, 2025. The company continues to leverage its strong position in the consumer health market, focusing on accessible self-care solutions. This announcement reflects Perrigo's commitment to returning value to its shareholders.
Price reaction · baseline $21.5093 (2025-10-29T16:56:00.000Z) · hit during market hours · clean, no other PRGO news in the window
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Perrigo declared a quarterly dividend of $0.290 per share.
  • The dividend is payable to shareholders on December 16, 2025.
  • Perrigo has a strong history in consumer health products.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+26%
120-day peak, hindsight
Typical move
1.3%
average across 3 past catalysts
Lead asset
Norgestrel
Phase 3 · Contraception

Full Press Release Details

DUBLIN,Oct. 29, 2025/PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of consumer health products,today announced that its Board of Directors declared a quarterly dividend of $0.290 per share, payable on December 16, 2025, to shareholders of record on November 28, 2025.

About Perrigo

Perrigo Company plc is a leading pure-play consumer health company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.
Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill®, Mederma®, Compeed®, EllaOne®,and Jungle Formula®.
For more information, visitwww.perrigo.com.

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's upcoming earnings release will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available athttps://investor.perrigo.com/sec-filings, for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2024.

Perrigo Contact

Frequently Asked Questions

What is the amount of Perrigo's declared dividend?

Perrigo declared a quarterly dividend of $0.290 per share.

When will the dividend be paid?

The dividend will be paid on December 16, 2025.

Who will receive the dividend?

Shareholders on record as of November 28, 2025, will receive the dividend.

What is Perrigo's focus in the market?

Perrigo focuses on providing high-quality consumer health products.

Last updated: Oct 29, 2025